C12Y 301/04
Phosphoric diester hydrolases
Official title: Phosphoric diester hydrolases (3.1.4)
C12Y301/04 (Phosphoric diester hydrolases) appears on 297 US grants and 553 published applications in this corpus.
Search patents in C12Y- Granted patents
- 297
- Published applications
- 553
- Assignees
- 239
- Inventors
- 890
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 9 |
| 2003 | 7 | 10 |
| 2004 | 4 | 13 |
| 2005 | 4 | 8 |
| 2006 | 3 | 7 |
| 2007 | 1 | 6 |
| 2008 | 2 | 11 |
| 2009 | 1 | 8 |
| 2010 | 4 | 9 |
| 2011 | 3 | 5 |
| 2012 | 3 | 9 |
| 2013 | 4 | 11 |
| 2014 | 15 | 17 |
| 2015 | 5 | 18 |
| 2016 | 14 | 27 |
| 2017 | 10 | 29 |
| 2018 | 18 | 44 |
| 2019 | 33 | 61 |
| 2020 | 25 | 36 |
| 2021 | 38 | 57 |
| 2022 | 22 | 45 |
| 2023 | 18 | 28 |
| 2024 | 24 | 32 |
| 2025 | 15 | 36 |
| 2026 | 11 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 301/04003Phospholipase c54
- C12Y 301/04012Sphingomyelin phosphodiesterase54
- C12Y 301/04001Phosphodiesterase i40
- C12Y 301/04004Phospholipase d27
- C12Y 301/04011Phosphoinositide phospholipase c27
- C12Y 301/040173',5'-cyclic-nucleotide phosphodiesterase17
- C12Y 301/04045N-acetylglucosamine-1-phosphodiester alpha-n-acetylglucosaminidase10
- C12Y 301/040533',5'-cyclic-amp phosphodiesterase8
All 29 subgroupsShow fewer
- C12Y 301/040353',5'-cyclic-gmp phosphodiesterase3
- C12Y 301/04052Cyclic-guanylate-specific phosphodiesterase3
- C12Y 301/04039Alkylglycerophosphoethanolamine phosphodiesterase2
- C12Y 301/040162',3'-cyclic-nucleotide 2'-phosphodiesterase1
- C12Y 301/040372',3'-cyclic-nucleotide 3'-phosphodiesterase1
- C12Y 301/04054N-acetylphosphatidylethanolamine-hydrolyzing phospholipase d1
- C12Y 301/04002Glycerophosphocholine phosphodiesterase0
- C12Y 301/04013Serine-ethanolaminephosphate phosphodiesterase0
- C12Y 301/04014[acyl-carrier-protein] phosphodiesterase0
- C12Y 301/04015Adenylyl-[glutamate--ammonia ligase] hydrolase0
- C12Y 301/04038Glycerophosphocholine cholinephosphodiesterase0
- C12Y 301/0404Cmp-n-acylneuraminate phosphodiesterase0
- C12Y 301/04041Sphingomyelin phosphodiesterase d0
- C12Y 301/04042Glycerol-1,2-cyclic-phosphate 2-phosphodiesterase0
- C12Y 301/04043Glycerophosphoinositol inositolphosphodiesterase0
- C12Y 301/04044Glycerophosphoinositol glycerophosphodiesterase0
- C12Y 301/04046Glycerophosphodiester phosphodiesterase0
- C12Y 301/04048Dolichylphosphate-glucose phosphodiesterase0
- C12Y 301/04049Dolichylphosphate-mannose phosphodiesterase0
- C12Y 301/0405Glycosylphosphatidylinositol phospholipase d0
- C12Y 301/04051Glucose-1-phospho-d-mannosylglycoprotein phosphodiesterase0
Recent patents
- Engineered phospholipase D mutants, methods of making engineered phospholipase D mutants, and uses thereof25 Aug 2026US 12,716,080 B2Cornell University
- Materials and methods for detecting and treating autoimmune movement disorders25 Aug 2026US 12,716,893 B2Mayo Foundation for Medical Education and Research
- Soluble ENPP1 proteins and uses thereof4 Aug 2026US 12,698,487 B2Biomarin Pharmaceutical Inc.
- Gene ZmPLD3 for inducing maize maternal haploid production and its application thereof28 Jul 2026US 12,692,507 B2China Agricultural University
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Laundry sanitizing compositions1 Oct 2026US 2026/0297458 A1Reckitt Benckiser N.V.
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases24 Sep 2026US 2026/0286363 A1Wylder Nation Foundation
- Methods for Sample Quality Assessment27 Aug 2026US 2026/0251658 A1SomaLogic Operating Co., Inc.
- Compound for treatment of erectile dysfunction30 Jul 2026US 2026/0216166 A1Initiator Pharma A/S
Most cited
By later US patents
- Methods of treating lysosomal storage diseases126US 6,537,785 B1Genzyme Glycobiology Research Institute, Inc. · 2003
- Compositions and methods for reprogramming eukaryotic cells103US 8,808,982 B2Cellscript, LLC · 2014
- Methods for producing highly phosphorylated lysosomal hydrolases86US 6,534,300 B1Genzyme Glycobiology Research Institute, Inc. · 2003
- Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription72US 10,266,850 B2Emmanuelle Charpentier · 2019
- Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription53US 10,407,697 B2The Regents of the University of California · 2019